Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
12:39a NOVARTIS : FDA OKs 2nd gene therapy for blood cancer; 1st for adults
10/18 GILEAD SCIENCES : Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes..
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18 GILEAD SCIENCES : UMass Medical Center and Dana-Farber Cancer Institute to recei..
10/18 GILEAD SCIENCES : Jay Flatley and John Martin to Be Named Recipients of Life Sci..
10/18 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
10/18 GILEAD SCIENCES : UMass Medical School shares $7.5M HIV grant
10/17 GILEAD SCIENCES : Announces Promotion of Alessandro Riva to Executive Vice Presi..
10/16 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
More news
News from SeekingAlpha
02:17a FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
12:18a J&J : Unattractive
10/18 Gilead cell therapy drug acquired via Kite Pharma wins FDA approval
10/18 The Math Behind the Gilead's Recent Merger
10/18 NETFLIX : Why It's Dangerous To Own Now
Financials ($)
Sales 2017 25 859 M
EBIT 2017 16 072 M
Net income 2017 10 607 M
Debt 2017 12 394 M
Yield 2017 2,64%
P/E ratio 2017 10,00
P/E ratio 2018 12,11
EV / Sales 2017 4,52x
EV / Sales 2018 5,02x
Capitalization 104 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 84,2 $
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS20.67%47 421
VERTEX PHARMACEUTICALS107.56%39 091
ACTELION23.24%29 925
GENMAB22.08%13 010
EXELIXIS, INC.66.06%8 318